FDA Approved: CIMERLI — Original Application (Coherus BioSciences Inc)

View source ↗

Summary

FDA approved CIMERLI (ranibizumab-eqrn) from Coherus as an original Biologics License Application. It is a biosimilar to ranibizumab (Lucentis) indicated for tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• CIMERLI (RANIBIZUMAB-EQRN)

Snippet

ORIG AP for CIMERLI (RANIBIZUMAB-EQRN)